Study design: This was a multicentre, prospective, randomised study. Objectives: To
compare the outcomes of intradetrusor and suburothelial onabotulinumtoxinA injections in …

Aim: The aim was to report the effectiveness and safety OnabotulinumtoxinA (Botox,
Allergan, Inc., Irvine, CA, USA) intradetrusor injections in spinal cord-injured (SCI) patients …

Objective To prospectively compare the results of intradetrusor onabotulinumtoxinA
injections and oral oxybutynin for urinary continence, urodynamic parameters and quality of …

Abstract Background Intradetrusor onabotulinumtoxinA (BoNT-ONA) injections have
become a well-established therapy for refractory neurogenic detrusor overactivity (NDO) …

Objectives To examine the efficacy and safety of onabotulinumtoxin A (B otox) injection into
the bladder wall for the treatment of neurogenic detrusor overactivity secondary to spinal …

BACKGROUND: Most reports in the literature on botulinum toxin A (BoNTA) therapy for
neurogenic detrusor overactivity (NDO) are based on the results of a single injection …

Purpose To explore the dose response to onabotulinumtoxinA 50, 100, and 200 U in
patients with spinal cord injury (SCI) with urinary incontinence (UI) due to neurogenic …

Introduction: Apart from the standard intramural administration of botulinum neurotoxin A
(BoNT/A) to the detrusor, intense research is taking place into new means of administration …

Purpose OnabotulinumtoxinA (BoNT-A) is a promising therapy for treating neurogenic
detrusor overactivity (NDO) in individuals with spinal cord injury (SCI). This systematic …

Objectives: To present a comprehensive experience with botulinum-A toxin (BTA) injected
into the detrusor muscle in patients with spinal cord injuries/diseases causing neurogenic …